NextCure (NASDAQ:NXTC) had its target price raised by Morgan Stanley from $25.00 to $33.00 in a research report sent to investors on Tuesday, AnalystRatings.com reports. Morgan Stanley currently has an overweight rating on the stock.

A number of other research analysts have also recently weighed in on NXTC. Bank of America initiated coverage on shares of NextCure in a report on Tuesday, July 9th. They issued a buy rating and a $25.00 price objective for the company. Piper Jaffray Companies initiated coverage on shares of NextCure in a report on Monday, June 3rd. They issued an overweight rating and a $26.00 price objective for the company.

Shares of NextCure stock opened at $26.71 on Tuesday. The business’s fifty day simple moving average is $18.87. NextCure has a 1 year low of $13.86 and a 1 year high of $27.89.

NextCure (NASDAQ:NXTC) last issued its earnings results on Monday, August 12th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.46) by ($0.15). The company had revenue of $1.40 million for the quarter, compared to analysts’ expectations of $1.50 million. As a group, analysts forecast that NextCure will post -2.14 EPS for the current year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC purchased a new position in NextCure in the second quarter valued at $96,000. Northern Trust Corp purchased a new stake in shares of NextCure during the second quarter worth about $337,000. Charles Schwab Investment Management Inc. purchased a new stake in shares of NextCure during the second quarter worth about $386,000. Indus Capital Partners LLC purchased a new stake in shares of NextCure during the second quarter worth about $1,407,000. Finally, Yale University purchased a new stake in shares of NextCure during the second quarter worth about $1,865,000. 2.06% of the stock is owned by institutional investors.

NextCure Company Profile

There is no company description available for NextCure Inc

Featured Article: How Do You Make Money With Penny Stocks?

Receive News & Ratings for NextCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NextCure and related companies with MarketBeat.com's FREE daily email newsletter.